Criteria Bio Ventures
Venture capitalBarcelona · Seed–Late Stage · 4 people tracked
Investment thesis
Criteria Bio Ventures is a life sciences venture fund that invests in biotech companies developing therapeutic approaches, primarily in Europe. The firm focuses on companies addressing unmet medical needs across multiple stages.
Team · 4 people
from the firm's websiteFrequently asked questions
- What stage does Criteria Bio Ventures invest at?
- Criteria Bio Ventures invests at the Seed, Series A, Series B, Series C, Late Stage stages.
- What sectors does Criteria Bio Ventures focus on?
- Criteria Bio Ventures focuses on Biotech, Medical Devices.
- Where is Criteria Bio Ventures located?
- Criteria Bio Ventures is headquartered in Barcelona, ES.
Similar investors
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
GV is Alphabet's venture capital arm, established in 2009 as Google Ventures. Operating with long time horizons and over $13 billion in assets under management, the firm invests across technology and life sciences sectors from seed to growth stages, supporting 400 active portfolio companies across North America, Europe, and Israel.
Khosla Ventures is a technology-focused investment firm that seeks companies leveraging disruptive technological advances to solve large-scale problems across multiple industries. The firm emphasizes proprietary technology, business model innovation, and early-stage, bold investments with unfair advantages.
A European investment firm established in 2016 by former Index Ventures life sciences professionals with over 20 years of experience in drug discovery and therapeutic development for unmet medical needs.